Automatic Website Traffic RSS

Progenics Pharmaceuticals (Part II): Explicating The Ramifications Of ...

Progenics Pharmaceuticals (Part II): Explicating The Ramifications Of The Azedra Approval Aug. 12, 2018 11:42 PM ET Progenics Pharmaceuticals, Inc. (PGNX) Stock BHC , BAYZF , PGNX , BHC:CA 65 ... read more

Progenics' Azedra Found Positive in Phase II Follow-Up Data - Nasdaq

Progenics Pharmaceuticals, Inc. ( PGNX) reported positive long-term follow-up data from a pivotal phase II study on its ultra-orphan radio-therapeutic candidate, Azedra, in patients suffering from ... read more

Progenics snags FDA nod for $300K ‘ultra-orphan’ cancer-fighter Azedra

To start, Progenics will target between 20 and 25 treatment centers, for use first on those that participated in Azedra’s clinical trials. “Part of what defines those 20 to 25 centers is a ... read more

Following Azedra’s Approval, Progenics Pharmaceuticals Announces ...

NEW YORK, July 31, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced financial results and provided a business update for the second quarter of 2018. “We ... read more

PROMETRIKA Extends Congratulations to Progenics Pharmaceuticals

CAMBRIDGE, Mass.--(BUSINESS WIRE)--PROMETRIKA, LLC extends its congratulations to our colleagues at Progenics Pharmaceuticals, Inc., on the recent approval of Azedra® (iobenguane I 131). read more

Progenics Pharmaceuticals provides update on timing of NDA submission ...

* Progenics - co was notified that commercial drug product manufacturing facility for Azedra needs more time to prepare for pre-approval inspection by FDA * Progenics Pharma - ‍data from pivotal ... read more

Progenics Pharmaceuticals Announces Three-Month ... - Markets Insider

NEW YORK, March 22, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and ... read more

Progenics Pharma Surges on FDA Decision - Yahoo Finance

Progenics Pharmaceuticals saw its shares make a solid gain to close out the year after the FDA accepted for review the firm’s New Drug Application (NDA) for Azedra. read more

Progenics Acquires AZEDRA® (iobenguane I 131 ... - Nasdaq

NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and ... read more

Progenics seeks new life for Azedra in ultra-orphan cancers

After a delay of nearly five years, Progenics Pharmaceuticals Inc. dosed the first patient in a resumed phase II registration study of the radiotherapeutic Azedra (Ultratrace iobenguane I 131). read more

Progenics Pharmaceuticals (Part II): Explicating The Ramifications Of ...

Progenics is an intriguing bioscience approaching its “growth inflection.”. As prognosticated, the company recently gained an FDA approval for its lead molecule, Azedra. Two approved ... read more